Laurion Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Laurion Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,128,889	Closed	-$7.54M	–	472
2023 Q3	$7.54M	Buy	1,128,889 +127,512	+13%	+$946K	0.05%	240
2023 Q2	$8.4M	Buy	1,001,377 +44,477	+5%	+$438K	0.05%	226
2023 Q1	$9.5M	Hold	956,900	–	–	0.06%	198
2022 Q4	$6.66M	Hold	956,900	–	–	0.03%	250
2022 Q3	$5.11M	Sell	956,900 -14,881	-2%	-$89.3K	0.03%	249
2022 Q2	$3.88M	Buy	+971,781	New	+$3.34M	0.06%	189
2018 Q4	–	Sell	-200,000	Closed	-$2.76M	–	1080
2018 Q3	$2.76M	Buy	+200,000	New	+$1.62M	0.03%	477

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Laurion Capital Management's ALDX Position: Q4 2023 in Review

Laurion Capital Management sold out of Aldeyra Therapeutics (ALDX) in Q4 2023, closing a stake of 1,128,889 shares — an estimated $7.54M sold.

Laurion Capital Management first reported a position in ALDX in Q3 2018 and held it in 7 quarters. The position peaked at $9.5M in Q1 2023. 105 funds tracked by Wall St. Rank hold ALDX as of Q4 2023.

Laurion Capital Management reported no remaining Aldeyra Therapeutics position as of Q4 2023 after selling out during the quarter.
Laurion Capital Management sold 1,128,889 Aldeyra Therapeutics shares in Q4 2023, an estimated $7.54M.
Laurion Capital Management first reported a position in Aldeyra Therapeutics in Q3 2018 and held it in 7 quarters.
Laurion Capital Management's Aldeyra Therapeutics position peaked at $9.5M in Q1 2023.
105 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2023.

Based on Laurion Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.